Re, 3rd. L., Haynes, K., Ming, E. E., Ives, W., Horne, L. N., Fortier, K., et al. (2012). Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3318
Re, L., Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q., et al. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000400